UTHSCSA Faculty Profiles v1.0
Xu, Kexin
Graduate School of Biomedical Sciences
Molecular Medicine
210-562-4148
xuk3@uthscsa.edu
|
|
| 2/2015 - Present |
Assistant Professor and Not Applicable |
UTHSCSA, Molecular Medicine, San Antonio, TX |
| Year |
Degree |
Discipline |
Institution |
| 2014 |
Postdoctoral Training |
Medical Oncology |
Dana-Farber Cancer Institute
Boston , MA |
| 2008 |
PhD |
Pharmacology |
University of Maryland, Baltimore
Baltimore , MD |
| 2001 |
BS |
Bioscience |
Wuhan University
Wuhan, Hubei , P. R. China |
cancer epigenomics -
My lab focuses on the mechanisms of epigenetics in cancer development and progression. We try to elucidate the roles of certain epigenetic landscape in regulation of chromatin structure, activities of master transcription factors, and subsequently context-specific gene expression patterns. |
Federal |
| Funding Agency |
NCI |
| Title |
NIH Pathway to Independence (R00) Award |
| Status |
Active |
| Period |
5/2015 - 5/2018 |
| Role |
Principal Investigator |
| Grant Detail |
The long-term goal of this proposed research is to elucidate the molecular mechanisms of EZH2 novel oncogenic functions in prostate cancer cells in the crosstalk with new interacting proteins identified from our proteomic analysis, such as β-catenin. |
State |
| Funding Agency |
CPRIT |
| Title |
CPRIT Award for the Recruitment of First-Time, Tenure Track Faculty Member |
| Status |
Active |
| Period |
3/2015 - 3/2019 |
| Role |
Principal Investigator |
| Grant Detail |
The goal of this study is to assess the efficacy of the small-molecule inhibitors of EZH2 in castration-resistant prostate cancer, and to develop a preclinical platform using cancer cell lines, animal models, and patient samples for the clinical translation of EZH2 as a therapeutic target in CRPC. |
